Calcimedica, Inc.
Clinical trials sponsored by Calcimedica, Inc., explained in plain language.
Clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Experimental drug auxora shows promise in severe COVID-19 pneumonia trial
Disease control CompletedThis study tested a drug called Auxora in 314 people with severe COVID-19 pneumonia. The goal was to see if it could help patients recover faster and reduce the need for breathing machines. Participants received either Auxora or a placebo, along with standard treatments. Results …
Phase: PHASE2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug shows promise for dangerous pancreatitis complication
Disease control CompletedThis study tested an experimental drug called CM4620-IE in 21 people with severe pancreatitis that caused body-wide inflammation (SIRS). The goal was to see if the drug is safe and to find the best dose for future studies. Participants received the drug plus standard care or stan…
Phase: PHASE2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug shows promise for speeding recovery in severe pancreatitis
Disease control CompletedThis study tested a drug called Auxora in 216 people hospitalized with acute pancreatitis and systemic inflammatory response syndrome (SIRS), a serious body-wide inflammation. Participants received either Auxora or a placebo daily for three days. The main goal was to see if Auxor…
Phase: PHASE2 • Sponsor: CalciMedica, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC